Clinical trials: Malaria, completed
Malaria, Pregnant
A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients
Randomized controlled single blind prospective comparative study
- Conditions
- Malaria, Pregnant, HIV
- Trial name
- NCT02527005
- Testing
- Sulphadoxine-pyrimethamine, Azithromycin
- Where
- Nigeria
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University of Ibadan
Malaria
Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria
The purpose of this study is to determine the efficacy of pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children.
- Trial name
- PAAL (NCT02411994)
- Testing
- Pyronaridine-artesunate, Artemether-lumefantrine combination
- Where
- Kenya
- Volunteers
- 197 people
- Sponsor
- Royal Tropical Institute
Malaria
Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults
The proposed study is a Phase 1 study with controlled human malaria infection (CHMI) designed primarily to evaluate the safety of the FMP012 combined with AS01B adjuvant system.
- Trial name
- NCT02174978
- Testing
- FMP012 with AS01B adjuvant system, P falciparum Controlled Human Malaria Infection (CHMI)
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Artemether-lumefantrine for Treatment of P. Falciparum Malaria in Brazil
This is an in vivo evaluation of drug efficacy performed in Cruzeiro do Sul, in the state of Acre, Brazil. A total of 81 participants ≥5 years old with parasitological confirmation of P.
- Trial name
- NCT02600767
- Testing
- Artemether-lumefantrine combination
- Where
- Brazil
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Malaria, Plasmodium Infections
Effectiveness of Mass Drug Administration for Reducing Seasonal Malaria Transmission in Zanzibar
The overall aim of this study is to determine the effectiveness of two rounds of mass drug administration (MDA) with dihydroartemisinin-piperaquine (DHAp) + single low dose (SLD) primaquine for reducing seasonal malaria…
- Trial name
- MaDrAZ (NCT02721186)
- Testing
- MDA with DHAp and SLD Primaquine
- Where
- Tanzania
- Volunteers
- 22,500 people, healthy volunteers welcome
- Sponsor
- Ulrika Morris
Plasmodium Falciparum Malaria
Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children
To assess the safety and reactogenicity of the FMP-1/AS02A malaria vaccine in malaria-exposed children living in western Kenya and aged 12-47 months
- Trial name
- NCT00317473
- Testing
- FMP1/AS02A Malaria vaccine, Imovax Rabies vaccine
- Where
- Kenya
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Vitamin A Deficiency, Malaria
Assessing Model Parameters for Applying the Retinol Isotope Dilution (RID) Method
For assessing body retinol pools in preschool children, it is recommended that a blood sample is taken 14-21 days after isotope dosing. During this period, dietary intake of vitamin A should be controlled.
- Conditions
- Vitamin A Deficiency, Malaria, Inflammation
- Trial name
- SUPERKID (NCT02996513)
- Testing
- Retinol Isotope Dilution (RID)
- Where
- Nigeria
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wageningen University
Malaria
Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali
This study tested the safety of a new malaria vaccine in adults in Mali, West Africa, and measured the ability of the vaccine to stimulate antibodies directed against the malaria protein that the vaccine is based on.
- Trial name
- NCT00308061
- Testing
- FMP1/AS02A, Imovax Rabies Vaccine
- Where
- Mali
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria, Plasmodium Falciparum Malaria
FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
Malaria is a disease that affects many people in Africa and in Mali. It is caused by germs that are spread by mosquito bites. This study will look at the safety, effectiveness, and best dose of an experimental malaria vaccine in…
- Trial name
- NCT00349713
- Testing
- FMP2.1/AS02A, Rabies vaccine (RabAvert)
- Where
- Mali
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313
This is a clinical trial in which healthy volunteers will be administered one or two experimental malaria vaccines. ChAd Pfs-IMX313 will either be administered alone or with MVA Pfs25-IMX313 in a prime-boost regime.
- Trial name
- NCT02532049
- Testing
- ChAd63 Pfs25-IMX313, MVA Pfs25-IMX313
- Where
- 2 sites in United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Diarrhea, Malaria
Impact Evaluation of Community-Based Health Programs in Rwanda
Community Health Clubs to improve local sanitation, hygiene and health conditions have been implemented in several countries in Africa and Asia with some success.
- Trial name
- CBEHPP (NCT01836731)
- Testing
- Classic Intervention, Minimum Intervention
- Where
- 2 sites in Rwanda
- Volunteers
- 8,718 people
- Sponsor
- Georgetown University
Malaria, Vivax
A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate
This will be a single-centre, 5-cohort, randomized open-label, parallel-group study in healthy volunteer subjects. This study aims to provide sufficient pharmacokinetic (PK) evidence to support the safe usage of Tafenoquine (TQ)…
- Trial name
- NCT02184637
- Testing
- Tafenoquine, Dihydroartemisinin + Piperaquine tetraphosphate, Artemether + Lumefantrine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Uncomplicated Knowlesi Malaria
P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine
Preliminary studies have supported the background efficacy of local standard anti-malarial medications in the treatment of uncomplicated knowlesi malaria, however there are no current WHO treatment guidelines for this infection.
- Trial name
- CAN KNOW (NCT02001012)
- Testing
- Artemether-lumefantrine combination, Chloroquine
- Where
- 3 sites in Malaysia
- Volunteers
- 123 people
- Sponsor
- Menzies School of Health Research
Malaria
Experimental Vaccine for Malaria
This study will examine the safety and immune response of healthy adult volunteers to AMA1-C1, an experimental malaria vaccine developed by the NIAID.
- Trial name
- NCT00114010
- Testing
- AMA1/Alhydrogel
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hemoglobin Mutations, Erythrocyte Variants
Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research
This study will collect blood samples for use in laboratory studies of malaria. The World Health Organization reports that 40 percent of the world's population is at risk for malaria, mostly in the poorest countries.
- Trial name
- NCT00277849
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum, Plasmodium Vivax Malaria
PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
This study, conducted at Johns Hopkins University Center for Immunization Research in Washington DC, will test the safety and immune response of healthy volunteers to two experimental malaria vaccines.
- Trial name
- NCT00295581
- Testing
- PpPfs25/ISA51 & ScPvs25/ISA51
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum Malaria, Vaccines
Experimental Vaccine for Plasmodium Falciparum Malaria
This study will evaluate the safety of two experimental malaria vaccines in healthy volunteers and examine their immune response to them.
- Trial name
- NCT00340431
- Testing
- MSP1(42)-FVO & MSP1(42)-3D7
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Severe Malaria, Malaria
Severe Malaria and Anti-malarial Drug Resistance in Cambodia
This study, conducted by the National Center for Malaria Control of Cambodia's Ministry of Health, the Guangzhou University of Traditional Chinese Medicine in the People's Republic of China, and the U.S.
- Conditions
- Severe Malaria, Malaria, Antimalarial Drug Resistance
- Trial name
- NCT00341003
- Where
- Cambodia
- Volunteers
- 2,090 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Malaria Vaccine in Children in Mali
This study will test an experimental vaccine called AMA1-C1 in children to see if it is safe and if it reduces episodes of malaria parasitemia (parasites in the blood) in children exposed to malaria.
- Trial name
- NCT00341250
- Testing
- AMA1-C1/Alhydrogel Malaria Vaccine
- Where
- 2 sites in Mali
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Filarial Infection
Immune Response Regulation in People Infected Concurrently With Malarial and Filarial Parasites
This study, conducted by NIH and the University of Bamako in Mali, Africa, will study the effect of concurrent infections with malaria and filariasis on patients' immune response.
- Trial name
- NCT00341666
- Where
- Mali
- Volunteers
- 360 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)